Certain early-stage changes to the prostate very rarely develop into aggressive cancer, but are still called that. Would it create a false sense of security to not call these “cancer” at all?
A new method of analysing the crystals in dehydrated blood could lead to a quicker, cheaper and less painful technique to diagnose, early detect, and monitor prostate cancer.
Combining risk markers, systematic evaluation of MRI images and AI, researchers aim to predict the risk of prostate cancer more accurately than before. This could save many patients from a biopsy.
The interpretation of prostate MRI is notoriously difficult. Annotating AI shows promise to help improve diagnostic performance through increased cancer detection rates with fewer false positives.
Radiotherapy of prostate cancer often comes with side effects, causing some patients to discontinue treatment. New research shows the benefits of at lowering the dose over subsequent treatment cycles.
A new study shows that extracellular vesicles shed by prostate cancer cells contain tumor-derived material that can be used as biomarkers of therapy response and resistance in metastatic disease.
US researchers have developed and validated a new urine-based test for prostate cancer, which was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection.
A new SPECT/CT imaging technique using lead-212 (²¹²Pb) shows promise in targeted alpha therapy (TAT) for patients with metastatic castration-resistant prostate cancer.
A three-part ‘multiparametric’ MRI of the prostate is standard of care in the UK for patients suspected of having prostate cancer. Now, a study shows two-part scans are sufficient for diagnosis.
Prostate radiotherapy techniques have been transformed over the past two decades. One promisting technique in this context is magnetic resonance-guided radiotherapy. The latest clinical results show a dramatic reduction in side effects, improving patient outcomes and quality of life.
How often should men get checked for their level of PSA, a marker for prostate cancer? A German study involving over 12,500 men shows that a five-year interval between tests is safe.
Dutch researchers use PSMA targeting to improve detection of prostate cancer, improving nodal staging and guiding more accurate surgery for this important patient population.
Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer which could revolutionise how the disease is diagnosed and treated in the future.
Targeting a specific protein, Finnish researchers may have found a way to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment.
US researchers discuss three blood-based liquid biopsies, namely circulating tumor cells, circulating tumor DNA and tumor-derived exosomes, as they relate to prostate cancer management.
In a new study, UCLA researchers demonstrated how small cell neuroendocrine prostate cancer tumor cells can arise from less aggressive prostate tumors.
Bone scans have been found to overstage prostate cancer at initial staging compared to prostate specific membrane antigen (PSMA) PET, according to new research.
Philips and Quibim have signed a multi-year agreement to work on an integrated solution including an AI-based software to automate real-time prostate gland segmentation in MR images.
Cancer has become strikingly more common in people under 50 in the past three decades, an international research team finds. The reseachers explore what this means for future death tolls.
Combining ultrasound and MRI technology can help detect prostate cancer at an earlier stage and potentially save lives, according to new University of Dundee research.
The accuracy of prostate-specific antigen (PSA) screening can be improved by including genetic factors that cause changes in PSA levels not associated with cancer, according to a multi-center study.
Experts argue that shared decision policies between patients and their doctors have led to high rates of PSA testing and clear medical harm, with minimal benefit and inequity.
Like the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer.
A new clinical trial has shown that men diagnosed with prostate cancer can benefit from ‘radical radiotherapy’ that delivers treatment in five hospital visits instead of the typical 20.
An advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a clearer view of suspected tumours during biopsy.
